NONOF News and Press, Novo-Nordisk A/S From 04/09/24

2024-04-09 13:06:07 ET More on Eli Lilly Eli Lilly: Three Threats To Its Huge Rally Why Eli Lilly And Rival Novo Nordisk Won't Be Troubled By Viking's Latest Weight Loss Data Eli Lilly: Diabetes And Weight Management Treatments Are The Winning Tickets EMA to ...

2024-04-09 11:30:10 ET Summary Today, we take a look at Novo Nordisk A/S, whose growth is being powered by Wegovy and Ozempic. The GLP-1 market is projected by some to grow to $100 billion by 2030 and Novo Nordisk is currently the preeminent player in this burgeoning space. Ho...

2024-04-03 07:01:03 ET More on Novo Nordisk Shaping The Future Of Obesity Treatment: GLP-1 Agonists At The Forefront Novo Nordisk: My 'Hold' Thesis For 2024 - The Premium Must Be Justified Novo Nordisk, A Very Healthy Pharma Stalwart CVS, Elevance Health to c...

2024-03-31 06:22:14 ET Summary Omega Therapeutics is a biotech company focused on developing programmable epigenomic mRNA medicines to control gene manifestation. The company's platform has applications in various diseases, including hepatocellular carcinoma, non-small cell lung c...

2024-03-28 10:00:53 ET More on CVS, Elevance Health, etc. Elevance: A Healthy Dose Of Dividend Growth Shaping The Future Of Obesity Treatment: GLP-1 Agonists At The Forefront CVS Health: Here Comes The Floor - Inherent Undervaluation Triggers Great Upside Potential ...

2024-03-27 19:50:00 ET Summary Positive results achieved from phase 2 MOMENTUM study, whereby patients not only achieved significant weight loss over a 48-week period with pemvidutide but also had lean mass preservation. It is said that the GLP-1 market could exceed $100 billion b...

2024-03-27 11:55:00 ET Summary Giverny Capital is a Montreal-based investment advisor specializing in private wealth management that also offers financial planning services. For the year ending December 31st 2023, the return for the Rochon Global Portfolio was 24.3% versus 17.5% f...

2024-03-27 08:26:15 ET More on Altimmune Altimmune: Taking On Toughest Of Rivals In Obesity - I'm Unconvinced By Recent Rally Altimmune's Pemvidutide Lacks Differentiation In Obesity Treatment Thoroughly Derisked, Altimmune Is Now A Great Buy Altimmune Q4 202...

2024-03-26 14:15:37 ET More on Amazon, Eli Lilly, etc. Amazon: Still Cheap Even After Robust Rally Amazon Faces Off Against Temu: Who Will Win? Eli Lilly: The Party Is Not Over Amazon making same-day prescription delivery available in NYC and LA Novo ...

2024-03-24 07:15:00 ET Summary Shanghai WuXi Biologics (HK: 2269) has broken ground on a $1.4 billion facility in Singapore, the first CRDMO to offer end-to-end biologics research, development and manufacturing in the city-state. Novo Nordisk announced plans to invest $556 million...